Novo Nordisk, The Maker of Weight Loss Drugs Wegovy and Ozempic, Will Cut Costs by Hiring Fewer New People. The Danish Company is suffering from Competition and Counterfeit Products of Their Popular Drug Wegovy.
At Novo Nordisk, there is a global hiring freeze for all jobs not relationships to the production of weight loss drugs. The Company Announced this to News Agency Reuters on Wednesday.
The Danish Producer is Suffering from Copycats Who Are Counterfeiting Wegovy, A Drug Against Obesity. In Addition, The Company there is a suffering from intense competition from Eli Lilly, which is also active in the weight loss market.
Earlier This Year, Novo Nordisk Already Warned of Lower Sales. For Example, The Company Expects Revenue Growth of 8 to 14 percent for the whole of 2025, Lower than the Previous Expectation of 13 to 21 percent. Profit Growth Has Been Adjusted to 10 to 16 percent. Previously, This was 16 to 24 percent.
Earlier This Month, Chairman Mike Doustdar Announced That He is Considering Mass Layoffs to Reduce Costs.